Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 1"
topic_facet:"Medical Condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Myelofibrosis+and+Janus-associated+Kinase+Inhibitor-Intolerant+Myelofibrosis+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10028537Term%3A+MyelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Myelofibrosis+and+Janus-associated+Kinase+Inhibitor-Intolerant+Myelofibrosis+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10028537Term%3A+MyelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Myelofibrosis+and+Janus-associated+Kinase+Inhibitor-Intolerant+Myelofibrosis+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10028537Term%3A+MyelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (12)
1
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis - KRT-232-113
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis - KRT-232-113
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Phase: Phase 1
Filter aufheben
Thema: Medical Condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
12
Aufsätze
12
E-Artikel
12
E-Ressourcen
Zeitschriftentitel
12
WHO International Clinical Trials Registry Plat...
Thema
12
610
Medical Condition: Relapsed/Refractory Myelofib...
Phase: Phase 1
12
Recruitment Status: Authorised-recruitment may ...
12
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2023
4
2022
4
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
12
Englisch
Haven't found what you're looking for?
Wird geladen...